D68.31 - Hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors
- Applicable to Hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors
- The 2025 edition of ICD10-CM D68.31 became effective on October 1, 2024.
- This is the American ICD10-CM version of D68.31 - other international versions of ICD10 D68.31 may differ.
- D68.31 is a Non-Billable / Non-Specific ICD10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
- D68.31 Code should not be used for billing or reimbursement purposes as there are multiple ICD-10 CM codes below it that contain a greater level of detail.
- D68.31 - Hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors
- D68.31 - Hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors
- D68.311 - Acquired hemophilia
- D68.312 - Antiphospholipid antibody with hemorrhagic disorder
- D68.318 - Other hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors
Non-Billable/Non-Specific Code
The following codes above D68.31 contain annotation back-references that may be applicable to D68.31:
- Chapter: D50-D89 - Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Section: D65-D69 - Coagulation defects, purpura and other hemorrhagic conditions
- Category: D68 - Other coagulation defects
Browse other similar CM codes:
Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.
Please, give attribution to our website icd10all.com